Variability of response to anti-thrombotic drug - Analysis of profile of coagulation and fibrinolysis in patients receiving total hip replacement (THR)

Variability of response to anti-thrombotic drug - Analysis of profile of coagulation and fibrinolysis in patients receiving total hip replacement (THR) - Variability of response to anti-thrombotic drug - prof ile of coagulation and fibrinolysis in patients receiving THR

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006337

Enrollment

100

Registered

2011-09-13

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

osteoarthritis of the hip, hip fracture

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients receiving THR and anticoagulants post THR for VTE prevention

Exclusion criteria

Exclusion criteria: 1) patients without consent 2) AST > or = 3 x upper limit or ALT > or = 3 x upper 3) serum CRTNN > 2 mg/dl 4) Hb = or < 10 g/dl, or platelet = or < 100k 5) drug allergy to anticoagulants 6) patients with malignancy under treatment or planning to start treatment within one year 7) primary physician thinks it is inappropriate to enroll the patient

Design outcomes

Primary

Measure	Time frame
plasma concentrations of markers of coagulation and fibrinolysis at the time-point of three weeks after THR	—

Secondary

Measure	Time frame
occurrence of symptomatic VTE, clinically proven bleeding symptom (TIMI major or minor), plasma concentrations of markers of coagulation and fibrinolysis at the time-point of first visiting after discharge	—

Countries

Japan

Contacts

Public ContactKenji Yokoyama

Keio University, School of Meidicine Division of Hematology, Department of Medicine

keyokoya@sc.itc.keio.ac.jp03-3353-1211

Outcome results